Safety and Immunogenicity of an Inactivated EV71 Vaccine in Infants
This study has been completed.
Sponsor:
Sinovac Biotech Co., Ltd
Information provided by (Responsible Party):
Sinovac Biotech Co., Ltd
ClinicalTrials.gov Identifier:
NCT01421121
First received: July 22, 2011
Last updated: November 26, 2012
Last verified: November 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A randomized, placebo-controlled, double-blind clinical trial is to evaluate the safety and immunogenicity of a new inactivated EV71 vaccine developed by Sinovac Biotech CO., LTD.
| Condition | Intervention | Phase |
|---|---|---|
|
Infection, Viral, Enterovirus |
Biological: 100U EV71 vaccine with adjuvant Biological: 200 U EV71 vaccine with adjuvant Biological: 400U EV71 vaccine with adjuvant Biological: 200U EV71 vaccine without adjuvant Biological: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver) Primary Purpose: Prevention |
Further study details as provided by Sinovac Biotech Co., Ltd:
Primary Outcome Measures:
- Neutralization antibody geometric mean titer in infants 28 days after immunization with EV71 vaccine with or without aluminium hydroxide adjuvant [ Time Frame: 6 month ] [ Designated as safety issue: No ]Primary immunogenicity end point were geometric mean titer of neutralization antibody againt EV71 virus >= 1:8
Secondary Outcome Measures:
- The rates and severity of solicited adverse events in infants following immunization as a Measure of Safety and Tolerability [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site.
solicited general adverse events include Fever, Nausea, Vomiting, Diareahhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy
| Enrollment: | 540 |
| Study Start Date: | June 2011 |
| Study Completion Date: | December 2011 |
| Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 100U EV71 vaccine with adjuvant
120 infants received 2 doses of 100U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
|
Biological: 100U EV71 vaccine with adjuvant
inactivated vaccine (vero cell) against EV71 of 100U /0.5ml, two doses, 28 days interval
Other Name: EV71 vaccine
|
|
Experimental: 200 U EV71 vaccine with adjuvant
120 infants received 2 doses of 200U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
|
Biological: 200 U EV71 vaccine with adjuvant
inactivated vaccine (vero cell) against EV71 of 200U /0.5ml, two doses, 28 days interval
Other Name: EV71 vaccine
|
|
Experimental: 400U EV71 vaccine with adjuvant
120 infants received 2 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
|
Biological: 400U EV71 vaccine with adjuvant
inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
Other Name: EV71 vaccine
|
|
Experimental: 200U EV71 vaccine without adjuvant
60 infants received 2 doses of 200U EV71 vaccine without adjuvant 28 days apart
|
Biological: 200U EV71 vaccine without adjuvant
inactivated vaccine (vero cell) against EV71 without adjuvant of 200U /0.5ml, two doses, 28 days interval
Other Name: EV71 vaccine
|
|
Placebo Comparator: Placebo
120 infants received 2 doses of placebo 28 days apart.
|
Biological: Placebo
0.5ml placebo, two doses, 28 days interval
Other Name: Placebo
|
Eligibility| Ages Eligible for Study: | 6 Months to 35 Months |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Healthy males and females, aged from 6 months to 11 years old Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator
- Provided legal identification for the sake of recruitment.
- Subjects and/or parent(s)/legal guardian(s) are able to understand and sign informed consents.
- Birth weight more than 2500 grams
Exclusion Criteria:
- History of Hand-foot-mouth Disease
- Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine
- Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
- Congenital malformations or developmental disorders, genetic defects, or severe malnutrition
- Epilepsy, seizures or convulsions history, or family history of mental illness
- Autoimmune disease or immunodeficiency, or parents, brothers and sisters have autoimmune diseases or immunodeficiency
- History of asthma, angioedema, diabetes or malignancy
- History of thyroidectomy or thyroid disease that required medication within the past 12 months
- Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
- Asplenia, functional asplenia or any condition resulting in the absence or removal the spleen
- Acute illness or acute exacerbation of chronic disease within the past 7 days
- Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
- History of any blood products within 3 months
- Administration of any live attenuated vaccine within 28 days
- Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or allergy treatment within 14 days
- Axillary temperature > 37.0 centigrade before vaccination
- Abnormal laboratory parameters before vaccination
- Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01421121
Locations
| China, Guangxi | |
| GuangXi Center for Diseases Control and Prevention | |
| Nanning, Guangxi, China | |
Sponsors and Collaborators
Sinovac Biotech Co., Ltd
Investigators
| Principal Investigator: | Yan-pin Li, MD | Guangxi Centers for Disease Control and Prevention |
More Information
No publications provided
| Responsible Party: | Sinovac Biotech Co., Ltd |
| ClinicalTrials.gov Identifier: | NCT01421121 History of Changes |
| Other Study ID Numbers: | EV71-1001-II |
| Study First Received: | July 22, 2011 |
| Last Updated: | November 26, 2012 |
| Health Authority: | China: Food and Drug Administration |
Additional relevant MeSH terms:
|
Virus Diseases Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013